Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 plus pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma (non‑nasopharyngeal) and other solid tumors
CTR20241895Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, pembrolizumab in head and neck squamous cell carcinoma (HNSCC), Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started Jun 2024; status: active.
02
Drugs
izalontamab brengitecanpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241895.